EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Emerging evidence of immunotherapy for colorectal cancer

Yuji Miyamoto iD, Katsuhiro Ogawa, Mayuko Ohuchi, Ryuma Tokunaga, Hideo Baba iD

Annals of Gastroenterological Surgery · 2023-03 · 7 (2) · 216-224

DOI: 10.1002/ags3.12633 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Annals of Gastroenterological Surgery, online erschienen am 08.11.2022. Verfasst von Yuji Miyamoto und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterological Surgery, Graduate School of Medical Sciences Kumamoto University Kumamoto Japan. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 102 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Since the advent of immune checkpoint inhibitors, which modulate the interplay between the tumor cell and immune system, immunotherapy has become widely recognized as a new standard treatment for cancers including microsatellite instability‐high (MSI‐H) colorectal cancer. Immune checkpoint inhibitors such as pembrolizumab and nivolumab (anti‐PD‐1 antibodies) that act in the effector phase of T cells and ipilimumab (anti‐CTLA‐4 antibody) that acts mainly in the priming phase are now in clinical use. These antibodies have shown therapeutic efficacy in MSI colorectal cancer patients who have failed to respond to existing standard therapies. Pembrolizumab is also strongly recommended as first‐line therapy for MSI‐H metastatic colorectal cancer. Therefore, the MSI status and tumor mutation burden of the tumor should be clarified before starting treatment. Because many patients do not respond to immune checkpoint inhibitors, combination therapies with immune checkpoint inhibitors, including chemotherapy, radiotherapy, or molecularly targeted agents, are being investigated. Furthermore, treatment methods for preoperative adjuvant therapy for rectal cancer are being developed.

Schlagwörter

Stichwörter der Autor:innen

immune checkpoint inhibitorlocally advanced rectal cancermetastatic colorectal cancermicrosatellite instability

Autor:innen und Institutionen

  • Department of Gastroenterological Surgery, Graduate School of Medical Sciences Kumamoto University Kumamoto Japan.

ORCID-Profile: Yuji Miyamoto, Hideo Baba

Förderung

  • Japan Society for the Promotion of Science

Zitieren

APA

Miyamoto, Y., Ogawa, K., Ohuchi, M., Tokunaga, R., & Baba, H. (2023). Emerging evidence of immunotherapy for colorectal cancer. Annals of Gastroenterological Surgery, 7(2), 216-224. https://doi.org/10.1002/ags3.12633

Vancouver

Miyamoto Y, Ogawa K, Ohuchi M, Tokunaga R, Baba H. Emerging evidence of immunotherapy for colorectal cancer. Annals of Gastroenterological Surgery. 2023;7(2):216-224. doi:10.1002/ags3.12633

BibTeX
@article{Miyamoto2023,
  author = {Miyamoto, Yuji and Ogawa, Katsuhiro and Ohuchi, Mayuko and Tokunaga, Ryuma and Baba, Hideo},
  title = {Emerging evidence of immunotherapy for colorectal cancer},
  journal = {Annals of Gastroenterological Surgery},
  year = {2023},
  volume = {7},
  number = {2},
  pages = {216--224},
  doi = {10.1002/ags3.12633}
}
Kostenlos starten →